Brief: Rocket Pharmaceuticals Phase 1 Trial To Evaluate Safety And Efficacy Of Rp-A701
30/06/2025 12:21
June 30 (Reuters) - Rocket Pharmaceuticals Inc RCKT.O: ROCKET PHARMACEUTICALS ANNOUNCES FDA IND CLEARANCE OF RP-A701 FOR THE TREATMENT OF BAG3-ASSOCIATED DILATED CARDIOMYOPATHY ROCKET PHARMACEUTICALS INC - PHASE 1 TRIAL TO EVALUATE SAFETY AND EFFICACY OF RP-A701 Source text: ID:nBw8CXjFta Further company coverage: RCKT.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Rocket Pharmaceuticals
See all newsRocket Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Rocket Pharmaceuticals posts Q2 profit helped by PRV sale
Brief: Rocket Pharmaceuticals Q2 EPS USD 1.08